Last edition
News about "rare disease drug development"
Accro Bioscience's AC-101 Enters NMPA Rare Disease Development Pilot Program
Accro Bioscience’s AC-101, a novel selective RIPK2 inhibitor, enters the NMPA CDE Caring Plan-Extension pilot program for rare disease drug development.
Rare Disease Drug Development | 14/09/2026 | By News Bureau | 107
US FDA Grants Orphan Drug Designation to Lundbeck's Asedebart for Cushing's Syndrome
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Lundbeck’s investigational anti-ACTH antibody asedebart for endogenous Cushing’s syndrome; a proof-of-concept trial is ongoing.
Rare Disease Drug Development | 14/09/2026 | By News Bureau
BioMarin to Acquire Alesta Therapeutics for Oral Hypophosphatasia Therapy ALE1
BioMarin will acquire Alesta Therapeutics for USD 275 million upfront, gaining ALE1, a potential first oral therapy for hypophosphatasia, plus milestone payments.
Rare Disease Drug Development | 20/08/2026 | By News Bureau | 112
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy